The Concept of Anti-Id Antibody

In a specific antibody molecule, the antigenic determinants located in the variable region are referred to as the idiotope of the antibody. The collective set of all idiotopes and paratopes within an antibody molecule is termed its idiotype (Figure 1). Antibodies targeting the idiotype of another antibody are called anti-idiotype antibodies (anti-ID antibodies). The concept of anti-idiotype antibodies was first proposed by Niels Jerne in 1974 as part of his immune network theory. This theory posits that the immune system functions as a complex network of interacting antibodies and lymphocytes. It laid the foundation for utilizing anti-idiotype antibodies as surrogate antigens in vaccines and therapeutics, particularly for targets that are challenging to produce or tolerate, such as carbohydrates, lipids, or tumor-associated antigens.

Classification of Anti-Id Antibody

Anti-idiotype antibodies are primarily classified into four categories based on their binding sites and functional properties (see Figure 2):

1. Type I Anti-idiotype Antibodies (Ab2α):

These bind to the idiotypic region of Ab1 but not to its paratope (antigen-binding site). Consequently, Ab2α cannot block the interaction between Ab1 and its antigen, lacking neutralizing or antigen-binding inhibitory activity.

2. Type II Anti-idiotype Antibodies (Ab2β):

Ab2β specifically recognizes the paratope of Ab1 (the region responsible for antigen binding). By structurally mimicking the original antigen, Ab2β is termed the "internal image of the antigen". It competitively inhibits Ab1-antigen binding, demonstrating potent neutralizing and blocking capabilities.

3. Type III Anti-idiotype Antibodies (Ab2γ):

Ab2γ binds to idiotopes adjacent to or partially overlapping with the paratope of Ab1. Unlike Ab2β, it does not structurally mimic the original antigen. However, it can still interfere with Ab1-antigen interactions through steric hindrance, thereby exhibiting partial neutralizing activity.

4.Type IV Anti-idiotype Antibodies (Ab2ε):

Generated by immunizing with Ab1-antigen complexes, these antibodies recognize hybrid epitopes composed of both the idiotope of Ab1 and portions of the bound antigen. Type IV antibodies are particularly useful for detecting or targeting immune complexes in diagnostic or therapeutic contexts.

Historical Development of Anti-Idiotype Antibody

In the mid-20th century, it was discovered that injecting antibodies into the same or different species could induce the production of antisera targeting those antibodies. Subsequently, it was found that antibody molecules possess two types of antigenic determinants: isotypes and allotypes. In 1955, Slater et al., while studying the specificity of rabbit antisera against human myeloma proteins, observed that antisera against certain myeloma proteins, after extensive absorption with unrelated myeloma proteins or normal human immunoglobulins (Ig), could still react with the original myeloma protein used as the immunogen ^[1]. They termed this new antigenic specificity on the antibody molecule as "individual antigenic specificities."

In 1963, Oudin et al. immunized 50 rabbits with Salmonella typhi. They isolated the anti-Salmonella typhi antibodies from one rabbit's serum and used them as immunogens to immunize normal rabbits ^[2]. The resulting antisera contained anti-antibodies. Research revealed that these anti-antibodies could only react with the anti-Salmonella typhi antibodies used as the immunogen and not with sera from the other 49 Salmonella typhi-immunized rabbits, nor with sera from rabbits immunized with other antigens or normal rabbit sera. This indicated that the anti-Salmonella typhi antibodies produced by this particular rabbit possessed unique antigenic determinants. These determinants differed from those found on antibody molecules produced by other individuals against the same antigen, as well as from those produced by the same individual against different antigens. Oudin named these unique antigenic determinants, distinct from isotypes and allotypes, "idiotypes."

In 1974, Jerne, based on modern immune-molecular understanding of antibody idiotypes and building on Burnet's "clonal selection theory," proposed the famous immune network theory. The immune network theory can be summarized as follows:

Ab1: The specific antibody produced in response to a foreign antigen, which contains idiotypes (Id). Ab2: The specific anti-idiotype antibody produced in response to the Id of Ab1. Jerne's immune network theory emphasized that Ab1 could induce Ab2, and through experiments, he further confirmed the existence of Ab3 ^[3].

It is well known that the shape of an antibody's antigen-binding region is complementary to the shape of its antigenic determinant. Similarly, certain Anti-Id antibodies produced against the idiotype of an antibody have a spatial configuration complementary to the idiotype's antigenic determinant. This double complementarity results in the antigen-binding region of the Anti-Id resembling the shape and amino acid distribution of the original antigen's determinant. In other words, from a molecular structure perspective, Anti-Id with this complementary configuration is equivalent to or approximates the original antigen molecule, much like a mirror image of the original antigen's determinant. Hence, it is referred to as the "internal image" of the antigen molecule ^[2]. In 1991, Nisonoff et al. pointed out that anti-idiotypic antibodies (specifically the Ab2β type) could essentially substitute for the antigen in inducing a specific immune response.

Applications of Anti-Id Antibody

Since the discovery of antibody idiotypes in the 1950s, anti-idiotype antibodies have undergone significant advancements. Initially, these antibodies were primarily utilized for vaccine development (e.g., idiotypic vaccines) and the treatment of autoimmune diseases. Today, anti-idiotype antibodies are extensively applied across multiple domains, including:

• Immunogenicity analysis of antibody-drug conjugates (ADCs),
• Clinical development of anti-drug antibodies (ADAs),
• Controls for ligand neutralization assays and antibody blocking assays,
• Pharmacokinetic (PK) and pharmacodynamic (PD) profiling of antibody therapeutics.

Conclusion

In summary, anti-idiotype antibodies are a fascinating and versatile class of immunoglobulins with significant potential in both therapeutic and diagnostic applications. Their ability to mimic antigens and modulate immune responses makes them valuable tools in the fight against a wide range of diseases. However, realizing their full potential will require continued research and innovation to address the challenges associated with their production and immunogenicity. As our understanding of the immune system continues to grow, so too will the opportunities for harnessing the power of anti-idiotype antibodies to improve human health.

GenScript——One stop Anti-ID antibody development service

Anti-ID antibody development service from GenScript covers diverse types of antigens, including antibody drugs, GCT drugs, peptide drugs, protein drugs, vaccines, oligonucleotide drugs, and small molecule drugs, and provides mouse and rabbit monoclonal antibodies for PK assay development and rabbit-derived ADA for immunogenicity test. The shortest turnaround time for rabbit ADA polyclonal development is 7 weeks, the shortest turnaround time for Anti-ID rabbit monoclonal antibody development is 9 weeks, and the shortest turnaround time for Anti-ID mouse monoclonal antibody development is 10 weeks. GenScript also provides one-stop services such as preparing peptides, proteins, mRNA, and oligonucleotide as antigen. Moreover, both antibody labeling and the development of PK/ADA kits after antibody development can be done at GenScript.

References

[1] SLATER RJ, WARD SM, KUNKEL HG. Immunological relationships among the myeloma proteins. J Exp Med. 1955 Jan 1;101(1):85-108. doi: 10.1084/jem.101.1.85.

[2] OUDIN J, MICHEL M. [A new allotype form of rabbit serum gamma-globulins, apparently associated with antibody function and specificity]. C R Hebd Seances Acad Sci. 1963 Jul 17;257:805-8.

[3] Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris). 1974 Jan;125C(1-2):373-89.